Actos & Bladder Cancer

Actos is a prescription drug that is used to help people with Type 2 diabetes regulate their blood sugar without insulin. However, taking the drug, manufactured by Takeda Pharmaceuticals U.S.A., Inc., has become linked with serious medical issues, including bladder cancer.

Deep concerns over the medication’s link to bladder cancer have caused Actos to be pulled from the market in France. In 2010, the US Food and Drug Administration began investigating the bladder cancer risk Actos poses to patients who’ve been taking the medication for more than two years.

Actos liability poses some very complex issues in both the fields of medical malpractice and product liability. In order to obtain the best resolution of your claim, you will need to work with an experienced attorney who is highly qualified in these areas.

If you or a loved one has been diagnosed with bladder cancer after taking Actos, speak with an Actos lawyer to understand more about the legal remedies that may be available to you.

Links to Bladder Cancer

The Food and Drug Administration analyzed a study that found a link between cases of bladder cancer among patients taking Actos. The 10-year study revealed that the patients often most susceptible to being diagnosed with serious medical conditions, such as bladder cancer, had taken Actos over an extended period of time. Some patients also experienced other symptoms and side effects that adversely affected their health.

Additionally, these studies show that the link between bladder cancer diagnosis and Actos is greater than what was revealed was originally believed from the clinical trials. In fact, the FDA reports that data given to the agency shows a 40 percent increased risk for patients who have taken Actos longer than one year. Despite such condemning results from various scientific studies, Actos is still available and prescribed to patients.

Actos Association with Bladder Cancer

In September 2010, the FDA announced that it was investigating the association between Actos and the greatly increased risk of developing bladder cancer that the medication poses. In June 2011, the FDA mandated the addition of a warning about this increased risk to the medication’s label. The FDA is recommending that health care professionals restrain from prescribing Actos to anyone with a history of bladder cancer.

Considerable evidence exists to suggest that Takeda Pharmaceuticals’ internal research had revealed the extent to which Actos increases the risk of bladder cancer. In 2002, at the FDA’s request, Takeda began a 10-year epidemiological study into the link between Actos and bladder cancer.

The five-year study results clearly showed that Actos increased the risk of bladder cancer. The company chose not to warn physicians and patients of this risk.

Meanwhile, a similar epidemiological study conducted in France led to the removal of pioglitazone from the French market. Although the medication is still being prescribed in Germany, German medical officials are not allowing it to be prescribed for new patients.

To date, over 1,300 Actos-related lawsuits have been filed in US federal courts. This number is expected to climb so precipitously that a judicial panel has ordered the transfer of all federal Actos-related litigation to the US District Court for the Western District of Louisiana for processing and handling as multidistrict litigation.

Many legal analysts are predicting that over 10,000 Actos patients will join this suit or other mass torts against Takeda in the next few years.